Last reviewed · How we verify

Merrem — Competitive Intelligence Brief

Merrem (Meropenem) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: meropenem. Area: Metabolic.

marketed meropenem Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Merrem (Meropenem) — Pfizer. Meropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Merrem TARGET Meropenem Pfizer marketed meropenem 1996-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (meropenem class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Merrem — Competitive Intelligence Brief. https://druglandscape.com/ci/meropenem. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: